title: Population pharmacokinetics of therapeutic monoclonal antibodies.
abstract: A growing number of population pharmacokinetic analyses of therapeutic monoclonal antibodies (mAbs) have been published in the scientific literature. The aims of this article are to summarize the findings from these studies and to relate the findings to the general pharmacokinetic and structural characteristics of therapeutic mAbs. A two-compartment model was used in the majority of the population analyses to describe the disposition of the mAb. Population estimates of the volumes of distribution in the central (V(1)) and peripheral (V(2)) compartments were typically small, with median (range) values of 3.1 (2.4-5.5) L and 2.8 (1.3-6.8) L, respectively. The estimated between-subject variability in the V(1) was usually moderate, with a median (range) coefficient of variation (CV) of 26% (12-84%). Between-subject variability in other distribution-related parameters such as the V(2) and intercompartmental clearance were often not estimated. Although the pharmacokinetic models used most frequently in the population analyses were models with linear clearance, other models with nonlinear, or parallel linear and nonlinear clearance pathways were also applied, as many therapeutic mAbs are eliminated via saturable target-mediated mechanisms. Population estimates of the maximum elimination rate (V(max)) and the mAb concentration at which elimination was at half maximum for Michaelis-Menten-type elimination pathways varied considerably among the different therapeutic mAbs. However, estimates of the total clearance (CL) of mAbs with linear clearance characteristics and of the clearance of mAbs via the linear clearance pathway (CL(L)) with parallel linear and nonlinear clearance were quite similar for the different mAbs and typically ranged from 0.2 to 0.5 L/day, which is relatively close to the estimated clearance of endogenous IgG of 0.21 L/day. The between-subject variability in the V(max), CL and CL(L) was moderate to high, with estimated CVs ranging from 15% to 65%. Measures of body size were the covariates most commonly identified as influencing the pharmacokinetics of therapeutic mAbs. In summary, many features of the population pharmacokinetics of currently used therapeutic mAbs are similar, despite differences in their pharmacological targets and studied patient populations.
authors.affiliation: Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
authors.forename: Nathanael L
authors.initials: NL
authors.lastname: Dirks
authors.forename: Bernd
authors.initials: B
authors.lastname: Meibohm
mesh_terms: D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D013329:Structure-Activity Relationship
chemical_list: D000911:Antibodies, Monoclonal
references.citation: J Pharmacokinet Biopharm. 1999 Aug;27(4):397-420
references.pmid: 10826130
references.citation: J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687-709
references.pmid: 17636457
references.citation: Trends Immunol. 2006 Jul;27(7):343-8
references.pmid: 16731041
references.citation: J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91
references.pmid: 19005743
references.citation: Br J Clin Pharmacol. 2007 May;63(5):548-61
references.pmid: 17096680
references.citation: Physiol Rev. 2003 Jul;83(3):871-932
references.pmid: 12843411
references.citation: J Pharmacokinet Biopharm. 1994 Jun;22(3):229-51
references.pmid: 7884651
references.citation: Clin Pharmacol Ther. 2001 Apr;69(4):201-9
references.pmid: 11309548
references.citation: J Clin Pharmacol. 2007 Sep;47(9):1104-18
references.pmid: 17766698
references.citation: J Pharmacol Exp Ther. 2008 Aug;326(2):555-62
references.pmid: 18460643
references.citation: Clin Pharmacol Ther. 2001 Jun;69(6):387-99
references.pmid: 11406736
references.citation: Invest New Drugs. 2004 Jan;22(1):39-52
references.pmid: 14707493
references.citation: AAPS J. 2005 Oct 05;7(2):E475-87
references.pmid: 16353925
references.citation: Cancer Chemother Pharmacol. 2005 Oct;56(4):361-9
references.pmid: 15868146
references.citation: J Immunol. 2004 Feb 15;172(4):2021-9
references.pmid: 14764666
references.citation: J Clin Rheumatol. 2007 Dec;13(6):355-8
references.pmid: 18176149
references.citation: Clin Immunol. 2007 Feb;122(2):146-55
references.pmid: 17046328
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3940-7
references.pmid: 12975461
references.citation: Nat Rev Immunol. 2007 Sep;7(9):715-25
references.pmid: 17703228
references.citation: J Clin Oncol. 2004 Jan 1;22(1):175-84
references.pmid: 14701780
references.citation: J Clin Invest. 1970 Apr;49(4):673-80
references.pmid: 5443170
references.citation: Antimicrob Agents Chemother. 1999 May;43(5):1183-8
references.pmid: 10223933
references.citation: J Clin Pharmacol. 2008 Mar;48(3):267-78
references.pmid: 18218786
references.citation: Drug Discov Today. 2006 Jan;11(1-2):81-8
references.pmid: 16478695
references.citation: J Clin Pharmacol. 2009 Feb;49(2):162-75
references.pmid: 19179295
references.citation: J Clin Pharmacol. 2009 Oct;49(10):1142-56
references.pmid: 19723673
references.citation: Biologics. 2008 Dec;2(4):645-53
references.pmid: 19707445
references.citation: Immunol Today. 1997 Dec;18(12):592-8
references.pmid: 9425738
references.citation: Endocrinology. 2001 Dec;142(12):5050-5
references.pmid: 11713196
references.citation: Curr Pharm Biotechnol. 2008 Dec;9(6):423-30
references.pmid: 19075682
references.citation: Blood. 2002 Feb 1;99(3):754-8
references.pmid: 11806974
references.citation: J Clin Pharmacol. 2007 May;47(5):553-65
references.pmid: 17379759
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1789-96
references.pmid: 18347005
references.citation: Int Immunol. 2003 Feb;15(2):187-95
references.pmid: 12578848
references.citation: Br J Clin Pharmacol. 2007 Sep;64(3):278-91
references.pmid: 17506867
references.citation: J Clin Pharmacol. 2005 Jul;45(7):792-801
references.pmid: 15951469
references.citation: J Clin Pharmacol. 2009 Sep;49(9):1012-24
references.pmid: 19620385
references.citation: Am J Physiol Renal Physiol. 2002 Feb;282(2):F358-65
references.pmid: 11788451
references.citation: Immunol Res. 1997 Feb;16(1):29-57
references.pmid: 9048207
references.citation: J Cell Sci. 2000 Apr;113 ( Pt 7):1277-85
references.pmid: 10704378
references.citation: J Pharm Sci. 2002 Jan;91(1):18-31
references.pmid: 11782894
references.citation: Clin Cancer Res. 2004 Nov 15;10(22):7555-65
references.pmid: 15569986
references.citation: Br J Clin Pharmacol. 2004 Oct;58(4):378-89
references.pmid: 15373930
references.citation: Br J Clin Pharmacol. 2001 Feb;51(2):177-80
references.pmid: 11259992
references.citation: J Biol Chem. 2002 Aug 2;277(31):28038-50
references.pmid: 12023961
references.citation: Clin Pharmacokinet. 2007;46(5):417-32
references.pmid: 17465640
references.citation: J Pharmacokinet Biopharm. 1999 Apr;27(2):213-30
references.pmid: 10567956
references.citation: Pharm Res. 2005 Jul;22(7):1088-100
references.pmid: 16028009
references.citation: Eur J Clin Pharmacol. 2009 Dec;65(12):1211-28
references.pmid: 19756557
references.citation: J Clin Invest. 1999 Oct;104(7):903-11
references.pmid: 10510331
references.citation: Clin Pharmacol Ther. 1998 Jul;64(1):66-72
references.pmid: 9695721
references.citation: Annu Rev Pharmacol Toxicol. 1992;32:185-209
references.pmid: 1605567
references.citation: AAPS J. 2005 Oct 05;7(2):E363-73
references.pmid: 16353916
references.citation: Ann Pharmacother. 2004 Oct;38(10):1702-6
references.pmid: 15328391
references.citation: Pharm Res. 1990 Feb;7(2):167-9
references.pmid: 2137911
references.citation: Clin Pharmacol Ther. 1994 Sep;56(3):248-52
references.pmid: 7924119
references.citation: Ther Drug Monit. 2008 Aug;30(4):523-9
references.pmid: 18641542
references.citation: J Cell Sci. 1999 Jul;112 ( Pt 14):2291-9
references.pmid: 10381385
references.citation: Br J Cancer. 2008 Mar 11;98(5):900-6
references.pmid: 18319714
references.citation: J Clin Pharmacol. 2007 Feb;47(2):227-37
references.pmid: 17244774
references.citation: Int Immunol. 2001 Dec;13(12):1551-9
references.pmid: 11717196
references.citation: Aliment Pharmacol Ther. 2004 Mar 1;19(5):511-9
references.pmid: 14987319
references.citation: J Pharm Sci. 2004 Sep;93(9):2184-204
references.pmid: 15295780
references.citation: Pharm Res. 2006 Jun;23(6):1275-84
references.pmid: 16715358
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):345-51
references.pmid: 15579493
references.citation: Lancet. 1966 Nov 19;2(7473):1087-93
references.pmid: 4162525
references.citation: Biochem Pharmacol. 2006 Jun 28;72(1):1-10
references.pmid: 16469301
references.citation: Pediatr Transplant. 2008 Jun;12(4):447-55
references.pmid: 18466432
references.citation: Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12
references.pmid: 19505189
references.citation: Eur J Pharm Biopharm. 2007 Nov;67(3):759-65
references.pmid: 17499981
references.citation: J Clin Oncol. 2000 Feb;18(4):904-14
references.pmid: 10673534
references.citation: Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86
references.pmid: 18205003
references.citation: Clin Pharmacol Ther. 1999 Sep;66(3):246-57
references.pmid: 10511060
references.citation: Clin Pharmacokinet. 2005;44(4):331-47
references.pmid: 15828849
references.citation: J Clin Pharmacol. 2008 Jun;48(6):681-95
references.pmid: 18401017
references.citation: Biologics. 2008 Jun;2(2):223-8
references.pmid: 19707356
references.citation: Clin Dev Immunol. 2004 Sep-Dec;11(3-4):205-13
references.pmid: 15559365
references.citation: Anticancer Drugs. 2007 Jan;18(1):7-15
references.pmid: 17159497
references.citation: J Clin Pharmacol. 2007 Mar;47(3):383-96
references.pmid: 17322150
references.citation: Prog Allergy. 1969;13:1-110
references.pmid: 4186070
references.citation: AAPS J. 2010 Mar;12(1):33-43
references.pmid: 19924542
references.citation: Hum Immunol. 2001 Feb;62(2):93-105
references.pmid: 11182218
references.citation: Curr Med Chem. 2007;14(18):1978-87
references.pmid: 17691940
references.citation: Clin Pharmacol Ther. 2008 Nov;84(5):548-58
references.pmid: 18784655
references.citation: J Clin Pharmacol. 2005 Apr;45(4):468-76
references.pmid: 15778428
references.citation: Br J Cancer. 1999 Dec;81(8):1419-25
references.pmid: 10604742
references.citation: J Pharm Sci. 2004 Nov;93(11):2645-68
references.pmid: 15389672
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6517-22
references.pmid: 17065274